Connection

SUZANNE FUQUA to Receptors, Progesterone

This is a "connection" page, showing publications SUZANNE FUQUA has written about Receptors, Progesterone.
Connection Strength

0.972
  1. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
    View in: PubMed
    Score: 0.176
  2. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.167
  3. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat. 1995 Sep; 35(3):233-41.
    View in: PubMed
    Score: 0.092
  4. The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat. 1993; 26(2):191-202.
    View in: PubMed
    Score: 0.076
  5. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012 Jun 14; 14(3):R95.
    View in: PubMed
    Score: 0.073
  6. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011 Dec 01; 71(23):7259-69.
    View in: PubMed
    Score: 0.070
  7. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21; 83(16):1157-60.
    View in: PubMed
    Score: 0.069
  8. Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice. Oncogene. 2009 Sep 10; 28(36):3177-87.
    View in: PubMed
    Score: 0.060
  9. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol. 2009 Apr; 23(4):454-65.
    View in: PubMed
    Score: 0.058
  10. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
    View in: PubMed
    Score: 0.022
  11. An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild-type estrogen receptor in human breast cancer. Cancer Res. 1993 Dec 15; 53(24):5882-4.
    View in: PubMed
    Score: 0.020
  12. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.019
  13. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15; 52(2):483-6.
    View in: PubMed
    Score: 0.018
  14. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
    View in: PubMed
    Score: 0.017
  15. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 01; 51(1):105-9.
    View in: PubMed
    Score: 0.017
  16. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997 Aug 15; 57(16):3486-93.
    View in: PubMed
    Score: 0.007
  17. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.006
  18. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15; 50(14):4332-7.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.